Skip to main content

Arnold & Porter Named to Global Competition Review's 2021 'GCR 100' Guide

December 15, 2020

For the 14th consecutive year, Global Competition Review has included Arnold & Porter in its annual "GCR 100" guide that lists the world's leading competition law and economics practices. The firm was ranked 5th in the GCR Global Elite. The firm was also ranked 3rd in GCR's list of the 10 best litigation practices.

In the past year, Arnold & Porter's antitrust/competition capabilities have been instrumental for clients in a variety of industries. Global Competition Review highlighted Arnold & Porter's representation of Sandoz against direct and indirect purchaser class actions in the Generic Pharmaceuticals Pricing antitrust litigation, as well as a suit brought by state attorneys general. GCR also noted the firm's representation of Bausch Health in the Glumetza antitrust litigation, as well as the firm's successful work for the Oakland Raiders, obtaining a dismissal of an antitrust lawsuit related to the professional football team's relocation to Las Vegas.

GCR also observed that Arnold & Porter's had a "strong" year on the deals side. "The firm advised on several complex and high-value deals, many of which were reviewed in-depth but approved without remedies," according to GCR. These deals include representation of Pfizer for the ex-US merger filings of its joint venture with GSK, combining the two companies' global consumer health businesses. The deal created the world's largest consumer health company with combined sales of approximately US $12.7 billion.

"Perhaps the firm's most high-profile deal matter is its representation of Fitbit in the company's €1.7 billion sale to Google, which received a second request from the US Department of Justice in December 2019. The deal is being closely followed by the global antitrust community as it raises novel questions about the assessment of data issues in merger control," GCR said.

GCR also noted Arnold & Porter's work as global competition counsel for Boston Scientific on its acquisition of BTG plc, which required antitrust approvals in seven countries. BTG is a UK public company, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. After a nearly nine-month investigation that included reviews in Austria, Spain and the US, Arnold & Porter secured clearances in all jurisdictions, with only the FTC requiring a remedy.

Arnold & Porter's international antitrust capabilities and clients were also featured in the guide's regional sections for Brussels; California; New York; and Washington, DC.

Debbie Feinstein leads Arnold & Porter's Global Antitrust practice, Jonathan Gleklen serves as chair of the firm's US Antitrust/Competition practice, and Luc Gyselen is head of the European Antitrust/Competition practice.

» Read the full Global Competition Review write-up here (subscription required).